Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with Abciximab

被引：26

作者：

Frilling, B

Zahn, R

Fraiture, B

Mark, B

Dönges, K

Becker, T

Siegler, KE

Seidl, K

Rustige, J

Senges, J

机构：

[1] Herzzentrum Ludwigshafen, Dept Cardiol, D-67063 Ludwigshafen, Germany

[2] Eli Lilly & Co, Hamilton, ON, Canada

[3] Lilly GmbH, Ludwigshafen, Germany

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 89卷 / 04期

关键词：

D O I：

10.1016/S0002-9149(01)02267-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A substantial number of patients undergoing percutaneous interventions have an impaired-renal function,(1) a condition that is associated with a variety of changes in metabolic and hemostatic systems.(2) There are only a few data on the application of abciximab in patients with impaired renal function. We used data from the Ludwigshafen IIb/IIIa-Antagonist Registry to analyze the safety and efficacy of abciximab for percutaneous coronary intervention (PCI) in patients with impaired renal function.

引用

页码：450 / +

页数：4

共 10 条

[1]

*AHA COMM REP, 1975, CIRCULATION, V51, P5

[2] UNSTABLE ANGINA - A CLASSIFICATION [J].

BRAUNWALD, E .

CIRCULATION, 1989, 80 (02) :410-414

[3] Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction [J].

Brener, SJ ;

Barr, LA ;

Burchenal, JEB ;

Katz, S ;

George, BS ;

Jones, AA ;

Cohen, ED ;

Gainey, PC ;

White, HJ ;

Cheek, HB ;

Moses, JW ;

Moliterno, DJ ;

Effron, MB ;

Topol, EJ .

CIRCULATION, 1998, 98 (08) :734-741

[4] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[5] A classification of unstable angina revisited [J].

Hamm, CW ;

Braunwald, E .

CIRCULATION, 2000, 102 (01) :118-122

[6]

Mezzano D, 1996, THROMB HAEMOSTASIS, V76, P312

[7]

Schuster S, 1997, Z KARDIOL, V86, P273, DOI 10.1007/s003920050059

[8]

Simoons ML, 1997, LANCET, V349, P1429

[9] Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade [J].

Topol, EJ ;

Lincoff, AM ;

Califf, RM ;

Tcheng, JE ;

Kleiman, NS ;

Adelman, AG ;

Burton, JR ;

Talley, JD ;

Ivanhoe, RJ ;

Ducas, C ;

Cheung, PK ;

Schick, U ;

Badard, D ;

Kramer, J ;

Leary, J ;

Snyder, H ;

Wilson, R ;

Dearen, M ;

Caramori, P ;

Webber, S ;

Taylor, J ;

Ferrando, T ;

Cohen, E ;

Balleza, L ;

Rouse, C ;

Hogg, N ;

Kelly, T ;

Alston, S ;

Webb, J ;

Buller, E ;

Ricci, DR ;

Mockman, S ;

Tanguay, JF ;

Poitras, AM ;

Timis, G ;

Davey, D ;

Coleman, P ;

Herrold-Runge, P ;

O'Neill, BJ ;

Foshey, K ;

Fitzgerald, N ;

Almond, D ;

Kostuk, W ;

White, J ;

Oskalns, R ;

Gottlieb, R ;

Koren, P ;

Palazzo, D ;

Azrin, M ;

Barry, MB .

LANCET, 1998, 352 (9122) :87-92

[10]

Topol EJ, 1997, NEW ENGL J MED, V336, P1689

← 1 →